References:
[1]
Concha
J, Tarazi M, Kushner CJ, Gaffney RG, Werth VP. The diagnosis and
classification of amyopathic dermatomyositis: a historical review and
assessment of existing criteria. Br J Dermatol 2019; 180: 1001-1008.
[2]
Ortiz-Santamaria
V, Babot A, Ferrer C. Anti-MDA5-positive dermatomyositis: an emerging
entity with a variable clinical presentation. SCAND J RHEUMATOL 2017;
46: 509-511.
[3]
Bendewald
MJ, Wetter DA, Li X, Davis MD. Incidence of dermatomyositis and
clinically amyopathic dermatomyositis: a population-based study in
Olmsted County, Minnesota. Arch Dermatol 2010; 146: 26-30.
[4]
Mukae
H, Ishimoto H, Sakamoto N, Hara S, Kakugawa T, Nakayama S et al..
Clinical differences between interstitial lung disease associated with
clinically amyopathic dermatomyositis and classic dermatomyositis. CHEST
2009; 136: 1341-1347.
[5]
Motegi
SI, Sekiguchi A, Toki S, Kishi C, Endo Y, Yasuda M et al.. Clinical
features and poor prognostic factors of anti-melanoma
differentiation-associated gene 5 antibody-positive dermatomyositis with
rapid progressive interstitial lung disease. EUR J DERMATOL 2019; 29:
511-517.
[6]
Lee
YJ, Kim DJ, Kim JS, Lee JH, Lee CT, Jheon S et al.. Experience and
results with VV-ECMO for severe acute respiratory failure: weaning
versus nonweaning. ASAIO J 2015; 61: 184-189.
[7]
Abrams
DC, Prager K, Blinderman CD, Burkart KM, Brodie D. Ethical dilemmas
encountered with the use of extracorporeal membrane oxygenation in
adults. CHEST 2014; 145: 876-882.
[8]
Chen
S, Hu J, Xu L, Brandon D, Yu J, Zhang J. Posterior Reversible
Encephalopathy Syndrome After Transplantation: a Review. MOL NEUROBIOL
2016; 53: 6897-6909.
[9]
Dhar
R. Neurologic Complications of Transplantation. NEUROCRIT CARE 2018; 28:
4-11.
[10]
Li J,
Liu Y, Li Y, Li F, Wang K, Pan W et al.. Associations between
anti-melanoma differentiation-associated gene 5 antibody and
demographics, clinical characteristics and laboratory results of
patients with dermatomyositis: A systematic meta-analysis. J DERMATOL
2018; 45: 46-52.
[11]
Gono
T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y et al..
Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of
response to treatment in interstitial lung disease with anti-MDA5
antibody-positive dermatomyositis. Rheumatology (Oxford) 2012; 51:
1563-1570.
[12]
Gan
YZ, Zhang LH, Ma L, Sun F, Li YH, An Y et al.. Risk factors of
interstitial lung diseases in clinically amyopathic dermatomyositis.
Chin Med J (Engl) 2020: 644-649.
[13]
Bakhshaee
M, Jokar MH, Mirfeizi Z, Atabati E, Tarighat S. Subcutaneous Emphysema,
Pneumomediastinum and Pneumothorax in a Patient with Dermatomyositis.
Iran J Otorhinolaryngol 2017; 29: 113-116.
[14]
Said
SA, Okamoto T, Sakanoue I, Unai S, Budev M, Akindipe O et al.. Lung
Transplant for Patient with Idiopathic Pneumonia Syndrome. ANN THORAC
SURG 2020.